 |
20 Diseases |  |
19 Trials |
|
19 Trials |  |
1670 News |  |
| «12...78910111213141516171819 |
- |||| Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (clinicaltrials.gov) - Jan 13, 2015
P3, N=236, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Dec 2017
- ||||| Zykadia (ceritinib) / Novartis
New P2 trial, Metastases: Ascend-7: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (clinicaltrials.gov) - Jan 13, 2015
P2, N=125, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Zykadia (ceritinib) / Novartis
Biomarker, New P1 trial, Combination therapy, Metastases: Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 22, 2014
P1, N=66, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Zykadia (ceritinib) / Novartis
Enrollment change: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Dec 7, 2014
P1, N=105, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Dec 2017 N=80 --> 105
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Nov 25, 2014
P1/2, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
N=80 --> 105 Trial primary completion date: Jun 2016 --> Sep 2016
- ||| Zykadia (ceritinib) / Novartis
New P1 trial, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 24, 2014
P1, N=150, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Zykadia (ceritinib) / Novartis, Kisqali (ribociclib) / Novartis
New P1/2 trial, Combination therapy: Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. (clinicaltrials.gov) - Nov 17, 2014
P1/2, N=170, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Zykadia (ceritinib) / Novartis
New P2 trial, Metastases: Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer (clinicaltrials.gov) - Nov 13, 2014
P2, N=10, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- ||||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
New P2 trial, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 27, 2014
P2, N=115, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Zykadia (ceritinib) / Novartis
Enrollment open: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Oct 11, 2014
P2, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- || Zykadia (ceritinib) / Novartis
Enrollment change, Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=69, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=142 --> 69 | Trial primary completion date: Dec 2014 --> Aug 2016
- |||| Zykadia (ceritinib) / Novartis
Trial primary completion date: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 11, 2014
P3, N=348, Recruiting, Sponsor: Novartis Pharmaceuticals
N=142 --> 69 | Trial primary completion date: Dec 2014 --> Aug 2016 Trial primary completion date: Dec 2017 --> Jun 2018
- ||| Zykadia (ceritinib) / Novartis
Enrollment change, Trial primary completion date, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Jun 2018 N=60 --> 100 | Trial primary completion date: Dec 2015 --> Jun 2016
- Zykadia (ceritinib) / Novartis
New P1 trial, Combination therapy, Metastases: Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 28, 2014
P1, N=108, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- ||| Zykadia (ceritinib) / Novartis
Trial initiation date, Trial primary completion date: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Aug 15, 2014
P2, N=90, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
N=60 --> 100 | Trial primary completion date: Dec 2015 --> Jun 2016 Initiation date: Jul 2014 --> Oct 2014 | Trial primary completion date: Mar 2018 --> Sep 2018
- ||||| Zykadia (ceritinib) / Novartis
New P2 trial: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (clinicaltrials.gov) - Jul 12, 2014
P2, N=90, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Zykadia (ceritinib) / Novartis
Enrollment open: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - May 27, 2014
P2, N=32, Recruiting, Sponsor: Yonsei University
Initiation date: Jul 2014 --> Oct 2014 | Trial primary completion date: Mar 2018 --> Sep 2018 Active, not recruiting --> Recruiting
- || Zykadia (ceritinib) / Novartis
Trial primary completion date: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - May 26, 2014
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Jan 2016
- | Zykadia (ceritinib) / Novartis
Trial completion date: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - May 26, 2014
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2015 --> Jan 2016 Trial completion date: Sep 2015 --> Jan 2016
- || Zykadia (ceritinib) / Novartis
Trial primary completion date: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (clinicaltrials.gov) - May 15, 2014
P2, N=141, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Aug 2014 --> Sep 2015
- ||| Zykadia (ceritinib) / Novartis
Trial initiation date: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - May 15, 2014
P2, N=126, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2014 --> Sep 2015 Initiation date: Dec 2012 --> Aug 2012
- || Zykadia (ceritinib) / Novartis
Trial completion date: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (clinicaltrials.gov) - May 15, 2014
P2, N=141, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2012 --> Aug 2012 Trial completion date: Aug 2014 --> Sep 2015
- ||| Zykadia (ceritinib) / Novartis
Enrollment change: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - May 15, 2014
P2, N=126, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2014 --> Sep 2015 N=105 --> 126
- ||| Zykadia (ceritinib) / Novartis
Enrollment closed: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - May 15, 2014
P2, N=126, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=105 --> 126 Recruiting --> Active, not recruiting
- ||| Zykadia (ceritinib) / Novartis
Trial initiation date, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Apr 27, 2014
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Feb 2014 --> Mar 2014
- |||| Zykadia (ceritinib) / Novartis
Enrollment open, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Apr 27, 2014
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Feb 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- ||||| Zykadia (ceritinib) / Novartis
Trial initiation date: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2014
P3, N=348, Ongoing, Sponsor: Novartis Pharma Services AG`NOVARTIS FARMA S.p.A.`Novartis Farmac
Not yet recruiting --> Recruiting Initiation date: Jul 2013 --> Aug 2013
- || Zykadia (ceritinib) / Novartis
Enrollment change: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 17, 2014
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2013 --> Aug 2013 N=65 --> 142
- Zykadia (ceritinib) / Novartis
Enrollment open: Effect of Hepatic Impairment on LDK378 Pharmacokinetics (clinicaltrials.gov) - Feb 3, 2014
P1, N=32, Recruiting, Sponsor: Novartis Pharmaceuticals
N=65 --> 142 Not yet recruiting --> Recruiting
- ||||| Zykadia (ceritinib) / Novartis
New P1/2 trial, Metastases: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (clinicaltrials.gov) - Jan 16, 2014
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
- || Zykadia (ceritinib) / Novartis
Enrollment closed: A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (clinicaltrials.gov) - Jan 12, 2014
P1, N=303, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Zykadia (ceritinib) / Novartis
Trial initiation date: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Oct 28, 2013
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Mar 2013 --> Aug 2013
- ||| Zykadia (ceritinib) / Novartis
Enrollment closed: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (clinicaltrials.gov) - Oct 21, 2013
P2, N=141, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Aug 2013 Recruiting --> Active, not recruiting
- Zykadia (ceritinib) / Novartis
New P2 trial: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Oct 15, 2013
P2, N=32, Active, not recruiting, Sponsor: Yonsei University
- Zykadia (ceritinib) / Novartis
Enrollment closed: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Oct 13, 2013
P2, N=32, Active, not recruiting, Sponsor: Yonsei University
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | Zykadia (ceritinib) / Novartis
New P1 trial: Effect of Hepatic Impairment on LDK378 Pharmacokinetics (clinicaltrials.gov) - Sep 23, 2013
P1, N=32, Recruiting, Sponsor: Novartis Pharmaceuticals
- Zykadia (ceritinib) / Novartis
Clinical: Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=0, Available, Sponsor: Novartis Pharmaceuticals
- |||||| Zykadia (ceritinib) / Novartis
Enrollment open, Metastases: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (clinicaltrials.gov) - Aug 2, 2013
P3, N=236, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Zykadia (ceritinib) / Novartis
Trial initiation date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 25, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Initiation date: Mar 2013 --> Jun 2013
- ||| Zykadia (ceritinib) / Novartis
Enrollment open: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 25, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- ||| Zykadia (ceritinib) / Novartis
Enrollment open: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Jul 25, 2013
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Zykadia (ceritinib) / Novartis
New P3 trial: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 8, 2013
P3, N=348, Ongoing, Sponsor: Novartis Pharma Services AG`NOVARTIS FARMA S.p.A.`Novartis Farmac
- |||||||||| Zykadia (ceritinib) / Novartis
New P3 trial, Metastases: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (clinicaltrials.gov) - Apr 8, 2013
P3, N=236, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Zykadia (ceritinib) / Novartis
New P1 trial: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 17, 2013
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Zykadia (ceritinib) / Novartis
Enrollment open: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - Jan 16, 2013
P2, N=105, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Zykadia (ceritinib) / Novartis
New P1 trial: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Dec 3, 2012
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Zykadia (ceritinib) / Novartis
New P2 trial: ASCEND-3: LDK378 in Crizotinib na (clinicaltrials.gov) - Sep 12, 2012
P2, N=105, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Zykadia (ceritinib) / Novartis
New P2 trial: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib (clinicaltrials.gov) - Sep 11, 2012
P2, N=141, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- Zykadia (ceritinib) / Novartis
Enrollment open: Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Sep 3, 2012
P1, N=25, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zykadia (ceritinib) / Novartis
New P1 trial: Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Jul 4, 2012
P1, N=25, Recruiting, Sponsor: Novartis Pharmaceuticals